Dear Reader,
CNBC's Jim Cramer once said: "I learned a long time ago not to be on the other side of a Chaikin trade."
Because his frequent Mad Money guest, Marc Chaikin, is Wall Street's "canary in the coalmine."
Since Chaikin accurately predicted the 2012 Priceline collapse, the 2020 crash, and the 2022 bear market, over 800,000 people have chosen to follow his Wall Street warnings.
And he's regularly tapped by Fox Business and CNBC to share his big market predictions, live on-air.
"This is when people get hurt," says Chaikin, who's traded through nine bear markets. "If you're holding Nvidia (NVDA) or FAANG right now, it's time to prepare for a massive shift."
Chaikin, who was hired to create three new indices for the Nasdaq, says that this shift will usher in the next wave of A.I. winners...
Sending multiple "under-the-radar" stocks shooting up 200%... 300%... even 500%.
All while potentially devastating investors holding the wrong A.I. stocks.
He told me: "We just uncovered multiple hidden AI stocks that have gone up 1,000% or more in mere weeks. If you've missed out on the hundreds of stocks that have doubled since the bottom in April, what's coming NEXT could be a defining moment in your financial life,"
Chaikin just announced the #1 hidden A.I. stock to buy today, 100% free.
His work is featured on every Bloomberg and Reuter's terminal on the planet, which cost over $32,000 a year to access.
But he's agreed to make his new A.I. warning available to the public, free of charge.
Because according to Chaikin, even Americans sitting on the sidelines right now will be impacted by what's coming.
Click here to access his new warning, and #1 A.I. stock recommendation.
Regards,
Vic Lederman
Publisher, Chaikin Analytics
CoreWeave and Madrigal's Insider Trades Flash Bullish Signals
Written by Leo Miller. Published 9/10/2025.
Key Points
- CoreWeave insiders have sold over $700 million in shares, with nearly half being discretionary sales—potentially signaling short-term caution despite long-term AI growth.
- Madrigal received European Union conditional approval for its MASH drug Rezdiffra, and Baker Bros. Advisors bought $62 million shares ahead of the news.
- While CoreWeave’s insider selling suggests limited near-term upside, Madrigal’s insider buying and exploding sales point to continued bullish momentum.
Recent insider trading activity is sending powerful signals to investors—one from a red-hot artificial intelligence (AI) infrastructure company, the other from a relatively under-the-radar pharmaceutical maker.
While insiders are offloading shares in CoreWeave (NASDAQ: CRWV), a major AI player, they're buying heavily into Madrigal Pharmaceuticals (NASDAQ: MDGL), a biotech company making waves. These divergent actions offer meaningful clues about each stock's near-term potential.
CoreWeave: Big Returns, Big Insider Selling
Reagan's former tech advisor sharing bombshell announcement (Ad)
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert.
He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.
Among the top-performing AI stocks of 2025, CoreWeave immediately comes to mind. Branded as a "neo-cloud" company built specifically for AI workloads—unlike traditional cloud providers—CoreWeave relies heavily on NVIDIA's (NASDAQ: NVDA) GPUs, spending billions to secure the most advanced hardware.
That partnership has fueled rapid growth and investor enthusiasm, helping shares soar approximately 123% year-to-date.
But after such a steep climb, insiders are starting to cash out. In Q3 alone, there was over $700 million worth of insider selling and no insider buying. Naturally, investors might wonder if insiders think the stock is overbought.
However, roughly $370 million of those sales were executed under 10b5-1 trading plans, which are pre-scheduled and don't necessarily reflect current sentiment.
The more telling figure is the remaining $350 million in Q3 sales outside of 10b5-1 plans. These discretionary sales—where insiders chose the timing and amount—offer a clearer bearish signal.
CoreWeave shares currently trade around $93, about 12% below the average insider exit price. That gap may provide a margin of safety for new investors, but if insiders see $100–$101 as a ceiling, the stock's near-term upside could be limited.
Wall Street price targets, however, remain bullish on balance. The MarketBeat consensus price target on CRWV is about $107. Some bulls, like Argus, even foresee a rise toward $200, while others, such as Moffett Nathanson, have a more conservative $65 target—highlighting the wide divergence in analyst views.
Madrigal: Shares Take Off After Insider Buys and EU Approval
While insiders at CoreWeave are selling, insiders at healthcare stock Madrigal Pharmaceuticals are buying aggressively. MarketBeat has tracked approximately $62 million in insider purchases during Q3—all by hedge fund Baker Bros. Advisors LP between Aug. 18 and Aug. 20. The weighted average purchase price was about $374 per share, and the stock has since climbed to around $454, delivering nearly a 20% gain for Baker Bros. in just weeks.
In the same quarter, Madrigal saw about $109 million of insider selling, almost entirely through 10b5-1 plans. As with CoreWeave, those pre-scheduled sales don't necessarily signal bearish sentiment, making the discretionary purchases by Baker Bros. the more bullish indicator.
Late in August, Madrigal received conditional approval in the European Union for its drug Rezdiffra—the first and only approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) in the EU. This opens a substantial new market for the company.
After U.S. approval, Rezdiffra's sales jumped from about $15 million in Q2 2024 to $213 million in Q2 2025. With an estimated 370,000 diagnosed MASH patients in Europe, European uptake could mirror—or even exceed—this growth.
Analysts share this optimism. MarketBeat's consensus price target for MDGL is around $471, with several firms citing EU approval and U.S. sales momentum as key catalysts. Backed by institutions like Vanguard, Paulson, and BlackRock, Madrigal appears well-positioned for further gains.
CRWV and MDGL Garner Positive Insider Indicators
Insider trading isn't a crystal ball, but when combined with strong fundamentals, it can offer valuable insight. At CoreWeave, insiders are locking in gains after a huge run-up. Some sales are routine, but discretionary exits suggest insiders see limited near-term upside—even as AI infrastructure demand remains robust.
Conversely, at Madrigal, the bold purchases by Baker Bros., coupled with EU approval and explosive Rezdiffra sales, signal strong confidence in the stock's future. For investors seeking opportunities, these insider moves at CRWV and MDGL highlight two compelling, yet contrasting, stories in AI and biotech.
This email message is a paid advertisement sent on behalf of Chaikin Analytics, a third-party advertiser of MarketBeat. Why was I sent this email?.
This ad is sent on behalf of Chaikin Analytics, 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. If you would like to optout from receiving offers from Chaikin Analytics please click here.
If you need assistance with your newsletter, please email our U.S. based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2025 MarketBeat Media, LLC.
345 N Reid Place #620, Sioux Falls, SD 57103. United States of America..